Randomized Phase II Study of Adjuvant WT-1 Analog Peptide Vaccine in Patients With Malignant Pleural Mesothelioma (MPM) After Completion of Combined Modality Therapy.

Trial Profile

Randomized Phase II Study of Adjuvant WT-1 Analog Peptide Vaccine in Patients With Malignant Pleural Mesothelioma (MPM) After Completion of Combined Modality Therapy.

Completed
Phase of Trial: Phase II

Latest Information Update: 27 Oct 2017

At a glance

  • Drugs Galinpepimut S (Primary) ; Montanide ISA-51; Sargramostim
  • Indications Mesothelioma
  • Focus Therapeutic Use
  • Most Recent Events

    • 08 Aug 2017 According to a joint media release by Galena Biopharma Inc. and SELLAS Life Sciences Group Ltd., status changed from active, no longer recruiting to completed.
    • 10 Jun 2017 Biomarkers information updated
    • 04 Jan 2017 Planned End Date changed from 1 Dec 2016 to 1 Dec 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top